Successful Management of Sepsis Following Liver Transplantation in an HIV-Positive Patient with Multiple Comorbidities: a case report

Introduction. Historically, HIV-infected patients were denied liver transplantation due to concerns about poorer outcomes compared to the non-infected population. Due to advances in antiretroviral therapy and improved understanding of the immunological status of these patients, transplantation has become a viable treatment option.

Case Description. This report describes a 56-year-old HIV-positive man with multiple comorbidities who underwent liver transplantation for end-stage liver disease due to chronic hepatitis B. The early post-transplantation period was complicated by severe sepsis, multiple organ failure, and graft dysfunction.

Treatment Methods. Comprehensive therapy included prolonged vasopressor support, renal replacement therapy, multiple blood transfusions, and targeted antimicrobial therapy.

Results. The patient was successfully treated and discharged in stable condition with a functioning graft.

Conclusion. This case demonstrates that even severe infectious complications after liver transplantation in polymorbid HIV-positive patients can be successfully treated with appropriate multidisciplinary intensive care.

1. 1 Di Benedetto F, De Ruvo N, Berretta M, et al. Don’t deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol. 2006;24(2).

2. 2 Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75(4):425-429.

3. 3 Tan-Tam CC, Frassetto LA, Stock PG. Liver and kidney transplantation in HIV-infected patients. AIDS Rev. 2009;11(4):190-204.

4. 4 Althoff KN, Gebo KA, Moore RD, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019;6(2).

5. 5 Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15(4):1001-1007.

6. 6 Costigliola P, Tumietto F, Zagnoli A, Chiodo F; Project HOST. Need for liver transplant in HIV-positive patients: first results of a specific survey in Italy, Project HOST. AIDS. 2003;17(14):2119-2121.

7. 7 Murillas J, Rimola A, Laguno M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl. 2009;15(9):1133-1141.

8. 8 Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138(1):159-164.

9. 9 Roland ME, Bernard L, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med. 2003;163(15):1773-1778.

10. 10 Botha J, Fabian J, Etheredge H, Conradie F, Tiemessen CT. HIV and solid organ transplantation: where are we now. Curr HIV/AIDS Rep. 2019;16(5):404-413.

11. 11 Novruzbekov M.S., Gulyaev V.A., Mazus A.I., Ivannikov E.V., Yadrikhinskaya M.S., Lutsyk K.N., Olisov O.D., Akhmetshin R.B., Magomedov K.M., Kazymov B.I., Akhmedov A.R., Alekberov K.F., Yaremin B.I. First experience of liver transplantation for HIV-positive patients in Russia. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2022;12(6):139-147. (In Russ.) https://doi.org/10.20340/vmi-rvz.2022.6.TX.1

12. 12 Petrara MR, Freguja R, Gianesin K, Zanchetta M, De Rossi A. Epstein-Barr virus-driven lymphomagenesis in the context of human immunodeficiency virus type 1 infection. Front Microbiol. 2013;4:311.

13. 13 Rieckmann P, Poli G, Fox CH, Kehrl JH, Fauci AS. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J Immunol. 1991;147(9):2922-2927.

14. 14 Takeshita S, Breen EC, Ivashchenko M, et al. Induction of IL-6 and IL-10 production by recombinant HIV-1 envelope glycoprotein 41 (gp41) in the THP-1 human monocytic cell line. Cell Immunol. 1995;165(2):234-242.

15. 15 Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583-587.

16. 16 Morscio J, Dierickx D, Tousseyn T. Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol. 2013;2013:150835.

17. 17 Wyndham-Thomas C, Delforge M, Mulkay JP, De Wit S. Barriers to liver transplantation in HIV infected patients. Acta Clin Belg. 2013;68(5):322-329.

18. 18 Zhang A, Zhang M, Shen Y, Wang W, Zheng S. Hepatitis B virus reactivation is a risk factor for development of post-transplant lymphoproliferative disease after liver transplantation. Clin Transplant. 2009;23(5):756-760.

19. 19 Yu F, Huang Y, Wang Y, Yu Z, Li X, Dong J. Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: a case report. Medicine (Baltimore). 2018;97(43)

20. 20 Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183.

21. 21 Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders. Cancer Treat Res. 2015;165:305-327.

22. 22 Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesisdriven treatment. Cancer Lett. 2015;369(1):37-44.

23. 23 Martinez OM, Krams SM. The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation. 2017;101(9):2009-2016.

24. 24 Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-1901.

25. 25 Zimmermann H, Trappe RU. EBV and posttransplantation lymphoproliferative disease: what to do? Hematology Am Soc Hematol Educ Program. 2013;2013:95-102.

26. 26 Liu M, Husain S, Famure O, Li Y, Kim SJ. Incidence, risk factors, clinical management, and outcomes of posttransplant lymphoproliferative disorder in kidney transplant recipients. Prog Transplant. 2019;29(2):185-193.

27. 27 Martínez-Calle N, Alfonso A, Rifón J, et al. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study. Eur J Haematol. 2017;98(1):38-43.

28. 28 Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R. Cancer biomarkers in HIV patients. Curr Opin HIV AIDS. 2010;5(6):531-537.

29. 29 Ladell K, Dorner M, Zauner L, et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol. 2007;9(8):2055-2069.

30. 30 Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1303-1314.

31. 31 Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:343-349.

32. 32 Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-2831.

33. 33 Ibrahim HA, Naresh KN. Posttransplant lymphoproliferative disorders. Adv Hematol. 2012;2012:230173.

34. 34 Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol. 2012;53(3):195-200.

35. 35 Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008;14(10):1077-1087.

36. 36 Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35(3):187-197.

37. 37 Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232-2273.

38. 38 Smets F, Sokal EM. Prevention and treatment for Epstein-Barr virus infection and related cancers. Recent Results Cancer Res. 2014;193:173-190.